EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudieNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis

Renzo Guerrini, Catherine Chiron iD, Delphine Vandame iD, Warren Linley iD, Toby Toward iD

Epilepsia Open · 2024

DOI: 10.1002/epi4.12923 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Epilepsia Open, 2024. Verfasst von Renzo Guerrini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, Children's Hospital Meyer IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Cannabidiol, Epilepsies, Myoclonic, Dioxolanes, Fenfluramine. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biocodex SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first‐line add‐on therapies in DS.

Methods

We conducted a systematic review and frequentist network meta‐analysis (NMA) of randomized controlled trial (RCT) data for licensed add‐on DS therapies. We compared the proportions of patients experiencing: reductions from baseline in monthly convulsive seizure frequency (MCSF) of ≥50% (clinically meaningful), ≥75% (profound), and 100% (seizure‐free); serious adverse events (SAEs); discontinuations due to AEs.

Results

We identified relevant data from two placebo‐controlled RCTs for each drug. Stiripentol 50 mg/kg/day and fenfluramine 0.7 mg/kg/day had similar efficacy in achieving ≥50% (clinically meaningful) and ≥75% (profound) reductions from baseline in MCSF (absolute risk difference [RD] for stiripentol versus fenfluramine 1% [95% confidence interval: −20% to 22%; p = 0.93] and 6% [−15% to 27%; p = 0.59], respectively), and both were statistically superior ( p < 0.05) to licensed dose regimens of cannabidiol (10 or 20 mg/kg/day, with/irrespective of clobazam) for these outcomes. Stiripentol was statistically superior in achieving seizure‐free intervals compared to fenfluramine (RD = 26% [CI: 8% to 44%; p < 0.01]) and licensed dose regimens of cannabidiol. There were no significant differences in the proportions of patients experiencing SAEs. The risk of discontinuations due to AEs was lower for stiripentol, although the stiripentol trials were shorter. Significance This NMA of RCT data indicates stiripentol, as a first‐line add‐on therapy in DS, is at least as effective as fenfluramine and both are more effective than cannabidiol in reducing convulsive seizures. No significant difference in the incidence of SAEs between the three add‐on agents was observed, but stiripentol may have a lower risk of discontinuations due to AEs. These results may inform clinical decision‐making and the continued development of guidelines for the treatment of people with DS. Plain Language Summary This study compared three drugs (stiripentol, fenfluramine, and cannabidiol) used alongside other medications for managing seizures in a severe type of epilepsy called DS. The study found that stiripentol and fenfluramine were similarly effective in reducing seizures and both were more effective than cannabidiol. Stiripentol was the best drug for stopping seizures completely based on the available clinical trial data. All three drugs had similar rates of serious side effects, but stiripentol had a lower chance of being stopped due to side effects. This information can help guide treatment choices for people with DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolEpilepsies, MyoclonicDioxolanesFenfluramineAnticonvulsantsDrug Therapy, CombinationSeizuresHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Dravet syndromecannabidiolfenfluraminenetwork meta‐analysisstiripentol

Substanzen

CannabidiolstiripentolDioxolanesFenfluramineAnticonvulsants

Autor:innen und Institutionen

  • Neuroscience Department, Children's Hospital Meyer IRCCS, Florence, Italy.
  • University of Florence, Florence, Italy.
  • INSERM U1141, NeuroDiderot, Université Paris Cité, Paris, France.
  • Pediatric Neurology and Reference Center for Rare Epilepsies, APHP, Necker-Enfants Malades Hospital, Paris, France.
  • Orphan Disease Division (HQ), Biocodex, Gentilly, France.
  • Paragon Market Access Ltd, Chorley, Lancashire, UK.

ORCID-Profile: Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward

Förderung

  • Biocodex SA

Zitieren

APA

Guerrini, R., Chiron, C., Vandame, D., Linley, W., & Toward, T. (2024). Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis. Epilepsia Open. https://doi.org/10.1002/epi4.12923

Vancouver

Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis. Epilepsia Open. 2024. doi:10.1002/epi4.12923

BibTeX
@article{Guerrini2024,
  author = {Guerrini, Renzo and Chiron, Catherine and Vandame, Delphine and Linley, Warren and Toward, Toby},
  title = {Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.12923}
}
Kostenlos starten →